ghk-cu nasal spray dosage 50mg GHK-CU 1mg – 30mL Nasal
Description
The Monkey Study (2001) Khavinson et al
Less necrosis developed in treated wounds, suggesting the peptide helped preserve marginally viable tissue that might otherwise have died
A dedicated phase 3 RENEW trial which investigates the efficacy and safety of the drug in patients with obesity or who were overweight, but without associated comorbidities is scheduled to start in late 2025.
Additionally, its involvement in managing stress and reducing anxiety could potentially contribute to enhancing sleep quality
